Astellas Takes Hostile $3.5 Bil. Bid To OSI Shareholders
Executive Summary
To publicize its hostile bid for OSI Pharmaceuticals, Astellas Pharma has registered the Web site oncologyleader.com. Call it hopefulness, call it hubris, but in the race to build an oncology business, Astellas is as far back in the pack as a 14,000-person global pharmaceutical firm can be
You may also be interested in...
The Rise Of Japanese Pharma Dealmakers
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.
The Rise Of Japanese Pharma Dealmakers
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.
Fierce Generic Competition Leads Astellas Into Tier-Based Pricing For Prograf In India
MUMBAI - Seventeen years after Prograf (tacrolimus) was first introduced into the market, Japan's second largest drug maker, Astellas Pharma, is still counting heavily on its blockbuster transplant drug to push future growth